Crockett A J, Cranston J M, Moss J R, Alpers J H
Division of Medicine, Cardiac and Critical Care Services, Flinders Medical Center, Bedford Park, South Australia, Australia.
Respir Med. 2001 Jun;95(6):437-43. doi: 10.1053/rmed.2001.1064.
This study aimed to review the evidence for the use of long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD). The design was a systematic Cochrane review of randomized controlled trials (RCTs) of long-term oxygen therapy for COPD and main outcome measure was survival on home oxygen therapy. Five RCTs were identified. Data from two trials of nocturnal oxygen therapy in mild to moderate hypoxaemia were aggregated. Data from the other three trials could not be aggregated because of differences in trial design and patient selection. Treatment with continuous versus nocturnal oxygen therapy produced a significant improvement in mortality after 24 months [Peto odds ratio 0.45, 95% confidence interval (95% CI) 0.25-0.81] for the continuous therapy group. Treatment with oxygen therapy versus no oxygen therapy showed a significant improvement in mortality after five years in the group receiving oxygen therapy (Peto odds ratio 0.42, 95% CI 0.18-0.98). There was no difference in mortality for patients with COPD and mild to moderate daytime hypoxaemia and nocturnal desaturation receiving nocturnal oxygen therapy versus no oxygen therapy or sham treatment. Long-term oxygen therapy versus no oxygen therapy in patients with COPD and moderate hypoxaemia had no effect on survival. In conclusion, long-term oxygen therapy improved survival in a selected group of COPD patients with severe hypoxaemia but few co-morbidities. Long-term oxygen therapy did not improve survival in patients with moderate hypoxaemia or in those with mild to moderate hypoxaemia and arterial desaturation at night.
本研究旨在综述慢性阻塞性肺疾病(COPD)患者使用长期氧疗的证据。研究设计为对COPD长期氧疗的随机对照试验(RCT)进行系统的Cochrane综述,主要结局指标是家庭氧疗的生存率。共识别出5项RCT。汇总了两项针对轻至中度低氧血症患者夜间氧疗试验的数据。由于试验设计和患者选择的差异,其他三项试验的数据无法汇总。连续氧疗组与夜间氧疗组相比,24个月后死亡率有显著改善[Peto比值比0.45,95%置信区间(95%CI)0.25 - 0.81]。氧疗组与无氧疗组相比,接受氧疗的组在5年后死亡率有显著改善(Peto比值比0.42,95%CI 0.18 - 0.98)。对于COPD且白天轻至中度低氧血症和夜间血氧饱和度下降的患者,夜间氧疗组与无氧疗组或假治疗组的死亡率无差异。COPD且中度低氧血症患者长期氧疗与无氧疗相比,对生存率无影响。总之,长期氧疗可改善部分重度低氧血症且合并症较少的COPD患者的生存率。长期氧疗并不能改善中度低氧血症患者或夜间轻至中度低氧血症且动脉血氧饱和度下降患者的生存率。